at MarketWatch.com (Jan 5, 2011)
Opexa Therapeutics (OPXA -2.9%) trades lower after the company reported a deeper Q2 loss and issued an update on its quarterly corporate developments. Losses grew as R&D costs nearly doubled on the company's preparation for Phase II trials of its lead MS drug therapy Tcelna. Additionally, the company says it's closed financing of its $4.1M private offering, and appointed current board member David Jorden as CFO, effective August 15.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs